Real-time SEC alerts Start Free →
Profitelligence
Bristol-Myers Squibb Company
BMY MEDIUM Impact

Bristol-Myers Squibb Company

Bristol-Myers Squibb Elects Directors and Approves Key Proposals at Annual Meeting

| 8-K |Healthcare

Summary

At the Annual Meeting held on May 5, 2026, Bristol-Myers Squibb Company's shareholders elected all 11 nominees to the board of directors, approved the compensation of named executive officers, ratified the appointment of Deloitte & Touche LLP as the independent auditor, and approved the 2026 stock award and incentive plan. However, they rejected a shareholder proposal to adopt a board policy that the chairperson of the board be an independent director.

Profitelligence Profitelligence Alerts

Get alerts for BMY

Be first to know when Bristol-Myers Squibb Company files with the SEC.

Set Up Alerts →

Filing Categories

Board Member Appointed Executive Compensation Detail Auditor Resignation Auditor Dismissed New Auditor Appointed Stock Plan Modification

Advertisement

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is a renowned pharmaceutical corporation engaged in the discovery, development, and distribution of innovative medicines. The company's core focus lies in providing therapeutic solutions for areas such as oncology, immunology, cardiovascular disease, and fibrotic diseases. Founded in 1887 and headquartered in New York City, it has grown into a key player in the global healthcare market, influencing medical advancements and treatment protocols. Bristol-Myers Squibb is pivotal for its groundbreaking contributions to cancer treatment, particularly through its development of immunotherapy drugs, which alter and assist the immune system's ability to fight cancer cells. Additionally, the firm extends its impacts across multiple sectors, affecting industries such as biotechnology, pharmaceuticals, and healthcare. The company's significance is underscored by its extensive research and development investments, often collaborating with research institutions and academic entities worldwide to pioneer new treatments. Such collaborations expand its influence beyond product distribution to shaping future healthcare landscapes. Bristol-Myers Squibb's commitment to innovation and addressing unmet medical needs makes it a prominent entity in the pharmaceutical sector.

Exchange: NYSE Industry: Drug Manufacturers - General Company Website →

Official SEC Documents

BMY
BMY Research
8Ks, insider trades, financials, technicals
SEC Alert Manager
Get alerts within 60 seconds of new filings

Advertisement